Bicycle Therapeutics (BCYC) Q4 Revenue Soars 1194.5% YoY to $48M, Crushing Estimates by 578%
Bicycle Therapeutics narrows Q4 loss to $0.29/share vs $0.95 estimate; revenue of $48M crushes $7.1M consensus by 578%.
Bicycle Therapeutics narrows Q4 loss to $0.29/share vs $0.95 estimate; revenue of $48M crushes $7.1M consensus by 578%.
Getty Images posts Q4 loss of $0.01 per share vs $0.02 estimate, though revenue of $282.3M beats consensus by 18.5%…
FinVolution posts $0.25 adjusted EPS on flat $432.4M revenue as eight analysts maintain unanimous Buy-or-better ratings.
Semtech posts Q4 EPS of $0.44, beating the $0.43 estimate by 2.0%, with revenue climbing 9.3% year-over-year to $274.4 million.
Dragonfly Energy posts $14.92 per share loss vs $0.30 estimate; Q4 revenue of $13.1M misses consensus $15M despite 6.9% YoY…
Microvast's GAAP EPS of $0.05 beat estimates, but adjusted loss of $0.11 and revenue miss of 26.6% reveal underlying weakness…
BW swings to $0.02 EPS vs. $0.05 loss estimate on $161M revenue, missing top-line consensus by 2.5% as margins drive…
Ampco-Pittsburgh reports $2.85 per share loss on $108.8M revenue, matching prior quarter's loss as adjusted EBITDA reaches $3.2M.
Black Diamond Therapeutics posted a narrower-than-expected Q4 loss of $0.14/share but missed revenue estimates with zero sales.
Digimarc swings to Q4 profit of $0.05 per share vs. consensus loss estimate, with revenue of $8.9M topping the $7.0M…